WallStSmart
OM

Outset Medical Inc

NASDAQ: OM · HEALTHCARE · MEDICAL DEVICES

$4.36
+2.11% today

Updated 2026-05-01

Market cap
$81.71M
P/E ratio
P/S ratio
0.68x
EPS (TTM)
$-5.37
Dividend yield
52W range
$3 – $22
Volume
0.2M

Outset Medical Inc (OM) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for OM.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 37 / 100
P/E (TTM)
Not meaningful for this profile
PEG
Margin of Safety
+83.59%
Fair value $27.66 vs $4.36
EV / EBITDA
0.0x

OM historical valuation range

Where current P/E sits in OM's own 5Y range.

Insufficient historical data for 5Y percentile analysis

OM intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

Current price
$4.36
Market value
Intrinsic value
$27.66
DCF estimate
Margin of safety
+83.59%
+534.4% upside to fair value

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

OM valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

Strong margin of safety
Current price 83.6% below DCF intrinsic value estimate. Meaningful downside cushion.

P/E Ratio — History

No historical P/E data available

P/S Ratio — History

Current: 0.68x

Is OM overvalued in 2026?

Outset Medical Inc (OM) currently trades at $4.36 per share with a market capitalization of $81,714,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 37/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

OM currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.7x, the market is valuing the company primarily on its revenue rather than its earnings.

Our discounted cash flow model estimates OM's intrinsic value at $27.66 per share, against the current market price of $4.36. This implies a margin of safety of +83.59%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.

The Piotroski F-Score of 6/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.

Bottom line: OM appears richly valued on our framework, with a Smart Value Score of 37/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is OM overvalued in 2026?

Based on a Smart Value Score of 37/100, OM appears overvalued. Current price exceeds what fundamentals currently justify.

What is OM's fair value?

Our DCF model estimates OM's intrinsic value at $27.66 per share, versus the current price of $4.36. This produces a margin of safety of +83.59%.

What P/E ratio does OM trade at?

OM does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.

Is OM a buy based on valuation?

WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 37/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.

How does OM's valuation compare to its history?

Insufficient historical valuation data exists yet for a confident percentile read on OM.

What is OM's Smart Value Score?

OM's Smart Value Score is 37/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.